

As below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

the specification of which

was filed on August 30, 2000 as United States Application No. 09/651,275.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

#### Prior Foreign Application(s) for which Priority is Claimed:

United States of America, 151436/60 of August 30, 1999

And I hereby appoint

Douglas B. Henderson, Reg.No. 20,291; Arthur S. Garrett, Reg.No. 20,338

Jerry D. Voight, Reg.No. 23,020; Herbert H. Mintz, Reg.No. 26,691;

Thomas L. Irving, Reg.No. 28,619; Thomas W. Winland, Reg.No. 27,605;

Martin I. Fuchs, Reg.No. 28,805; Susan H. Griffen, Reg.No. 30,907;

Richard B. Racine, Reg.No. 30,415; Thomas H. Jenkins, Reg.No. 30,857;

Carol P. Einaudi, Reg.No. 32,226; Frank E. Caffoe, Reg.No. 18,621;

Allen R. Jensen, Reg.No. 28,224; Bryan C. Diner, Reg.No. 32,409;

M. Paul Barker, Reg.No. 32,013; Charles E. Van Hom, Reg.No. 40,266;

David S. Forman, Reg.No. 33,694;

all of the firm of FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, Reg.No. 22,540, my attorneys, with full power of substitution and revocation to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Courts in connection therein, and specify that communications about the application are to be directed to the following correspondence

address:

FINNEGAN, HENDERSON, FARABOW, GARRETT AND DUNNER Franklin Square Bldg., Suite 700 1300 I Street, N.W. Washington, DC 20005-3315 Tel. 202-408-4000



INVENTOR(S) / R	tesidence
-----------------	-----------

1) Bernward Schölkens, Hölderlinstra	aße 62, 65779 Kelkheim, Germany	
Signature: Roversed Yel	The Date: 3/4/07	
2) Norbert Bender, Rheingaustraße 2	6, 65719 Hofheim, Germany	
Signature:	Date:	
3) Badrudin Rangoonwala, Dahlienwe	eg 11, 65719 Hofheim, Germany	
Signature:	Date:	
4) Gilles Dagenais, 670 Chemin des 0	Oies, StNicholas, Quebec, J7A 3P8, Canada	
Signature:	/ Date:	
5) Hertzel Gerstein, 5 Dromore Crescent, Hamilton, Ontario, L8S 4A8, Canada		
Signature:	Date:	
6) Salim Yusuf, 48 Woodend Drive, C	arlisle, Ontario, LOR 1H2, Canada	
Signature:	Date:	
The inventor is citizen of : 1) – 3) Germ	any; 4) – 6) Canada	
Post Office Address of all Inventors:	Aventis Pharma Deutschland GmbH Patent- und Lizenzabteilung Industriepark Höchst, Geb. K 801 65926 Frankfurt	

Germany



As below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

the specification of which

was filed on August 30, 2000 as United States Application No. 09/651,275.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

#### Prior Foreign Application(s) for which Priority is Claimed:

United States of America, 151436/60 of August 30, 1999

And I hereby appoint

Douglas B. Henderson, Reg.No. 20,291; Arthur S. Garrett, Reg.No. 20,338

Jerry D. Voight, Reg. No. 23,020; Herbert H. Mintz, Reg. No. 26,691;

Thomas L. Irving, Reg.No. 28,619; Thomas W. Winland, Reg.No. 27,605;

Martin I. Fuchs, Reg.No. 28,805; Susan H. Griffen, Reg.No. 30,907;

Richard B. Racine, Reg.No. 30,415; Thomas H. Jenkins, Reg.No. 30,857;

Carol P. Einaudi, Reg.No. 32,226; Frank E. Caffoe, Reg.No. 18,621;

Allen R. Jensen, Reg.No. 28,224; Bryan C. Diner, Reg.No. 32,409;

M. Paul Barker, Reg.No. 32,013; Charles E. Van Horn, Reg.No. 40,266;

David S. Forman, Reg.No. 33,694;

all of the firm of FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, Reg.No. 22,540, my attorneys, with full power of substitution and revocation to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Courts in connection therein, and specify that communications about the application are to be directed to the following correspondence address:

FINNEGAN, HENDERSON, FARABOW, GARRETT AND DUNNER Franklin Square Bldg., Suite 700 1300 I Street, N.W. Washington, DC 20005-3315 Tel. 202-408-4000



INVENTOR(S) / Residence		
1) Bernward Schölkens, Hölderlinstraf	3e 62, 65779 Kelkheim, Germany	
Signature:	Date:	
2) Norbert Bender, Rheingaustraße 26	6, 65719 Hofheim, Germany	
Signature: Nasart 730	22 dr Date: 3.5-01	
3) Badrudin Rangoonwala, Dahlienwe		
Signature:	Date:	
	ies, StNicholas, Quebec, J7A 3P8, Canada	
Signature:	Date:	
5) Hertzel Gerstein, 5 Dromore Crescent, Hamilton, Ontario, L8S 4A8, Canada		
Signature:	Date:	
6) Salim Yusuf, 48 Woodend Drive, Ca	rlisle, Ontario, LOR 1H2, Canada	
Signature:	Date:	
The inventor is citizen of : 1) – 3) Germany; 4) – 6) Canada		
Post Office Address of all Inventors:	Aventis Pharma Deutschland GmbH Patent- und Lizenzabteilung Industriepark Höchst, Geb. K 801 65926 Frankfurt	

Germany



As below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

the specification of which

was filed on August 30, 2000 as United States Application No. 09/651,275.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

#### Prior Foreign Application(s) for which Priority is Claimed:

United States of America, 151436/60 of August 30, 1999

And I hereby appoint

Douglas B. Henderson, Reg.No. 20,291; Arthur S. Garrett, Reg.No. 20,338

Jerry D. Voight, Reg.No. 23,020; Herbert H. Mintz, Reg.No. 26,691;

Thomas L. Irving, Reg.No. 28,619; Thomas W. Winland, Reg.No. 27,605;

Martin I. Fuchs, Reg.No. 28,805; Susan H. Griffen, Reg.No. 30,907;

Richard B. Racine, Reg.No. 30,415; Thomas H. Jenkins, Reg.No. 30,857;

Carol P. Einaudi, Reg.No. 32,226; Frank E. Caffoe, Reg.No. 18,621;

Allen R. Jensen, Reg. No. 28,224; Bryan C. Diner, Reg. No. 32,409;

M. Paul Barker, Reg.No. 32,013; Charles E. Van Horn, Reg.No. 40,266;

David S. Forman, Reg.No. 33,694;

all of the firm of FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, Reg.No. 22,540, my attorneys, with full power of substitution and revocation to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Courts in connection therein, and specify that communications about the application are to be directed to the following correspondence address:

FINNEGAN, HENDERSON, FARABOW, GARRETT AND DUNNER Franklin Square Bldg., Suite 700 1300 I Street, N.W. Washington, DC 20005-3315 Tel. 202-408-4000



INVENTOR(S) / Residence	
1) Bernward Schölkens, Hölderlinstraß	e 62, 65779 Kelkheim, Germany
Signature:	Date:
2) Norbert Bender, Rheingaustraße 26	, 65719 Hofheim, Germany
Signature:	Date:
3) Badrudin Rangoonwala, Dahlienweg	11, 65719 Hofheim, Germany
Signature: Badruslin Lango	onulale Date: 4.4.2001
N .	es, StNicholas, Quebec, J7A 3P8, Canada
Signature:	Date:
5) Hertzel Gerstein, 5 Dromore Crescer	
Signature:	Date:
6) Salim Yusuf, 48 Woodend Drive, Car	lisle, Ontario, LOR 1H2, Canada
Signature:	Date:
The inventor is citizen of : 1) – 3) German	ny; 4) – 6) Canada
Post Office Address of all Inventors:	Aventis Pharma Deutschland GmbH Patent- und Lizenzabteilung Industriepark Höchst, Geb. K 801 65926 Frankfurt

Germany



As below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

the specification of which

was filed on August 30, 2000 as United States Application No. 09/651,275.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

### Prior Foreign Application(s) for which Priority is Claimed:

United States of America, 151436/60 of August 30, 1999

And I hereby appoint

Douglas B. Henderson, Reg.No. 20,291; Arthur S. Garrett, Reg.No. 20,338

Jerry D. Voight, Reg.No. 23,020; Herbert H. Mintz, Reg.No. 26,691;

Thomas L. Irving, Reg.No. 28,619; Thomas W. Winland, Reg.No. 27,605;

Martin I. Fuchs, Reg.No. 28,805; Susan H. Griffen, Reg.No. 30,907;

Richard B. Racine, Reg.No. 30,415; Thomas H. Jenkins, Reg.No. 30,857;

Carol P. Einaudi, Reg.No. 32,226; Frank E. Caffoe, Reg.No. 18,621;

Allen R. Jensen, Reg.No. 28,224; Bryan C. Diner, Reg.No. 32,409; M. Bayl Barker, Rog No. 32,013; Charles E. Van Hom, Rog No. 40

M. Paul Barker, Reg.No. 32,013; Charles E. Van Hom, Reg.No. 40,266;

David S. Forman, Reg.No. 33,694;

all of the firm of FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, Reg.No. 22,540, my attorneys, with full power of substitution and revocation to prosecute this application, to make alterations and amendments therein, to file continuation and divisional applications thereof, to receive the Patent, and to transact all business in the Patent and Trademark Office and in the Courts in connection therein, and specify that communications about the application are to be directed to the following correspondence address:

FINNEGAN, HENDERSON, FARABOW, GARRETT AND DUNNER Franklin Square Bldg., Suite 700 1300 I Street, N.W. Washington, DC 20005-3315 Tel. 202-408-4000

INVENTOR(S) / Residence	
1) Bernward Schölkens, Hölderlinstraf	ße 62, 65779 Kelkheim, Germany
Signature:	Date:
2) Norbert Bender, Rheingaustraße 26	6, 65719 Hofheim, Germany
Signature:	Date:
3) Badrudin Rangoonwala, Dahlienwe	
Signature:	Date:
4) Gilles Dagenais, 670 Chemin des C	Dies, StNicholas, Quebec, J7A 3P8, Canada
Signature: Liver K. Dage	mair Date: April 17, 2001
5) Hertzel Gerstein, 5 Droghore Cresce	ent, Hamilton, Ontario, L8S 4A8, Canada  Date: <u>Apals (مر)</u>
6) Salim Yusuf, 48 Woodend Drive, Ca	
Signature:	Date: 2010 01
The inventor is citizen of : 1) - 3) Germa	any; 4) – 6) Canada
Post Office Address of all Inventors:	Aventis Pharma Deutschland GmbH Patent- und Lizenzabteilung Industriepark Höchst, Geb. K 801 65926 Frankfurt Germany